The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

As changes to Medicaid funding and enrollment requirements come into effect over the next few years, the Minnesota Department ...

Washington Post National Health Reporter Paige Winfield Cunningham discusses how the Trump administration is considering ...

A new state analysis found that up to 140,000 Minnesotans could lose health care coverage due to federal Medicaid spending ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

According to the American Hospital Association, Trump’s tax bill will result in 1.8 million people in rural communities ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...